We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.585 | 1.57 | 1.60 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.51 | 18.04M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/1/2020 16:03 | John, I really think you would have learned to be quiet now. You've all embarrassed yourselves. | davevt | |
31/1/2020 14:24 | Dave raised good point. I was thinking the same yesterday that why Andrew bought it only after placing. Still no reply of my email! | marie1980 | |
31/1/2020 14:01 | Give it a rest Dave... Go and find another share to doom and gloom...you bore us all... | johntopdog | |
31/1/2020 13:52 | Anyone notice that a director only bought shares after a placing, and only 5 grands worth. Doesn't give you much confidence eh. Didn't think the shares were worth more than 2p, doesn't want to invest any decent money, and technically traded on insider information as he personally would have known this price drop was coming. Not that you should take any notice of director deals anyway.....why? Because that director just got paid a load of money from said placing, it's not like the 5 grand he just spent came out of his own pocket, is it... | davevt | |
31/1/2020 10:47 | I agree dave. I was annoyed with your constant negative comments here but slowly I'm getting what you mean there. I'm also bit annoyed as Dr. and Andrew has so far not reply me. I chased them again as I type. | marie1980 | |
31/1/2020 10:31 | fully funded for the next 12 months.whats not to like? waiting for the in vivo results from car t and cdx manufacturabilty results next......then IND ,then development/licensin most pharma cos trade at @40mcap going into phase 1 trials all to play for! 8-12p | purple11 | |
31/1/2020 09:55 | fully funded for the next 12 months.whats not to like? waiting for the in vivo results from car t and cdx manufacturabilty results next......then IND ,then development/licensin most pharma cos trade at @40mcap going into phase 1 trials all to play for! 8-12p | purple11 | |
31/1/2020 09:35 | Well I did warn you Marie and you mocked me the other day, remember.? | davevt | |
31/1/2020 07:59 | True renal, but amount he purchased is hardly confidence booster for the market. That’s the amount many of board members purchased to average down price. I’m confident this is not the RNS lti need right now unfortunately | marie1980 | |
31/1/2020 07:48 | Always follow the financial directors purchases, a good sign methinks | renalrod | |
31/1/2020 07:17 | Andrew bought HEMO share. If I remember last time also he purchased worth £10,000 Not huge amount but he is the one accumulating. Strange - I’m still awaiting reply from him about subsidiary. Usually he reply in a day! | marie1980 | |
30/1/2020 21:53 | Yes Dave, you're so great and finally mummy loves you. | on target | |
30/1/2020 20:03 | filtered. complete idiot. | purple11 | |
30/1/2020 16:52 | and when they do we could be looking at massive upside. | purple11 | |
30/1/2020 16:04 | Indeed, and we need these discussions to come to a conclusion: "Work on the core CDX antibody project with the Company's major pharmaceutical partner continues to progress with successful results achieved in further laboratory tests and with discussions ongoing as to its future development and funding." | on target | |
30/1/2020 16:01 | Not so bad considering that we are trading at a premium to the new issue price.......and the company has circa 650k working capital. It's now up to Dr. Sandler to push CDX to the next level. | badger60 | |
30/1/2020 14:23 | You're welcome Badger, I've also included Andrew Wright ( CFO ) as previously he is the one who also give fast response. FYI, if you need details of their email: From: XXX Sent: 30 January 2020 06:17 To: 'headquarters@hemoge Subject: Subsidiary and concerns regarding Hemo's financial Let's be honest, so far Dave has been right in a way that HEMO has not achieved as we would have liked or as much as they promised earlier. Still there is no IND or even Phase1 trials. I re-read the RNS about £75K and i also put the concerns that agreement was with Immugenyx and why not with HEMO ? I've recently added more HEMO in my portfolio but now Dave has put some doubt in my thought process. Again, I will keep you posted about Dr/Andrew's email. I also requested them if I can meet them should they are in London next time. Again will keep you updated. Best, | marie1980 | |
30/1/2020 14:15 | to provide additional working capital for the Company to progress its core CDX antibody collaboration and to support its various partnerships with other major pharmaceutical companies. | purple11 | |
30/1/2020 14:14 | Fundraising done and dusted - Dave will have to close his short now. | on target | |
30/1/2020 14:12 | gone to good hands progress excellent | tsmith2 | |
30/1/2020 14:11 | Work on the core CDX antibody project with the Company's major pharmaceutical partner continues to progress with successful results achieved in further laboratory tests and with discussions ongoing as to its future development and funding | purple11 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions